Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Features of management of patients with pah associated with systemic connective tissue diseases in real clinical practice
https://doi.org/10.33667/2078-5631-2024-24-57-62
Abstract
The article deals with the problem of diagnosis of pulmonary arterial hypertension (PAH) in systemic connective tissue diseases. PAH is characterized by a progressive increase in pulmonary vascular resistance, which leads to the development of right ventricular heart failure and premature death of patients. The features of the management of patients with PAH associated with systemic connective tissue diseases in real clinical practice are presented. A clinical case is presented. The importance of early diagnosis, careful differential diagnosis and its verification using invasive methods for assessing central hemodynamics is noted. Early initiation of the initial pathogenetic combination therapy based on a comprehensive assessment of the risk of mortality and disease progression can improve not only clinical symptoms, exercise tolerance, indicators of biochemical markers, but also slow down the progression of the disease, is the key to improving the prognosis in patients with PAH. Comprehensive management of patients by a team of cardiologist and rheumatologist allows improving the volume and quality of medical care, taking into account the individual characteristics of the patient, and applying a personalized approach to therapy.
About the Authors
V. N. Tyupina
Novosibirsk Regional Clinical Cardiological Dispensary
Russian Federation
Russian Federation
Tyupina Victoria N, head of the Polyclinic Dept, leading cardiologist
Novosibirsk
L. D. Khidirova
Novosibirsk Regional Clinical Cardiological Dispensary; Novosibirsk State Medical University
Russian Federation
Russian Federation
Khidirova Lyudmila D., DM Sci (habil.), prof., head of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine; Cardiologist
Novosibirsk
References
1. Galiè N., Humbert M., Vachiery J., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Noordegraaf A., Beghetti M., Ghofrani A., Sanchez M., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L., Trindade P., Zompatori M., Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Russian Journal of Cardiology. 2016; (5): 5-64. (In Russ.). https://doi.org/10.15829/1560-4071-2016-5-5-64.
2. Titov O.V., Petrova M.E., Khidirova L.D. Genetic aspects of the formation of idiopathic pulmonary arterial hypertension. Medical science and education of the Urals. 2021; 22, 4 (108): 193-196. (In Russ.). https://doi.org/10.36361/1814-8999-2021-22-4-193-196.
3. Chung L, Liu J, Parsons L. et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138 (6): 1383-94.
4. Rich S, Dantzker DR, Ayres SM. et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987; 107: 216-23. https://doi.org/10.7326/0003-4819-107-2-216
5. Kane G.C, Maradit-Kremers H, Slusser J. et al. Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest. 2011; 139 (6): 1285-93. https://doi.org/10.1378/chest.10-1293.
6. Badesch DB, Raskob GE, Elliott CG. et al. Pulmonary Arterial Hypertension: Baseline Characteristics from the REVEAL Registry. Chest. 2010; 137: 376-87. https://doi.org/10.1378/chest.09-1140.
7. Shapiro S, Traiger G.L, Michelle Turner M. et al. Sex Differences in the Diagnosis, Treatment, and Outcome of Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management. Chest. 2012; 141 (2): 363-73. https://doi.org/10.1378/chest.10-3114.
8. Ling Y, Johnson M.R, Kiely D.G. et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am.J. Respir. Crit. Care Med. 2012 Oct 15; 186 (8): 790-6. DOI: 10.1164/rccm.201203-03830C
9. Humbert M, Sitbon O, Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 2006; 173: 1023-30. https://doi.org/:10.1164/rccm.200510-16680
10. McGoon MD, Benza RL, Escribano-Subias P. et al. Pulmonary Arterial Hypertension: Epidemiology and Registries. J. Am. College of Cardiology. 2013; 62 (25, Suppl D): 51-9. https://doi.org/:10.1016/j.jacc.2013.10.023
11. Chazova I. E., Arkhipova O.A., Martynyuk T.V. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Terapevticheskii arkhiv. 2019; 91 (1): 25-31. https://doi.org/: 10.26442/00403660.2019.01.000024.
12. Volkov A.V., Nikolaeva E.V., Iudkina N.N. i dr. Vliianie terapii sildenafilom na vyzhi-vaemost’ patsientov s legochnoi arterial’noi gipertenziei, assotsiirovannoi s sistem-nymi zabolevaniiami soedinitel’noi tkani (rezul’taty prospektivnogo nabliudeniia). Terapevt. arkh. 2015; 87 (11): 62-7. (In Russ.).
13. Galiè N. et al. Eur. Heart. J. 2016; 37: 67-119. https://doi.org/10.1093/eurheartj/ehv317.
14. Hoeper M.M. et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018, Int J. Cardiol. (2018). https://doi.org/10.1016/j.ijcard.2018.08.082.
15. Thakrar M.V. et al. Initial Combination Therapy With Riociguat and Ambrisentan in Pulmonary Arterial Hypertension: A Prospective Open-label Study. The Journal of Heart and Lung Transplantation. April 2018; 37 (4S). Abstract 113. Available at: https://www.jhltonline.org/article/S1053-2498(18)30116-5/abstract.
16. Dupuis J., Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur. Respir. J. 2008; 31: 407-415.
17. Gliè N, Hoeper M, Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal. October 2009; 30 (20): 2493-2537, https://doi.org/10.1093/eurheartj/ehp297.
18. Petrova M. E., Khidirova L. D., Titov O. V. Genetic risk factors for the development of idiopathic pulmonary arterial hypertension (differences in genetic background in children and adults) (a brief literature review). Bulletin of New Medical Technologies. 2021. Vol. 28, No. 3. P. 33-35. (in Russ.).
19. Badesch D.B, Tapson V.F, McGoon M.D. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000; 132 (6): 425-34. DOI: 10.7326 /0003-4819-1326-200003210-00002
20. Matucci-Cerinic M, Denton C.P, Furst D.E. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011; 70 (1): 32-8. https://doi.org/10.1136/ard.2010.13065
21. Chazova I.E., Martynyuk T.V., Valieva Z. S., Azizov V.A., Barbarash O. L. et all. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian heart journal. 2020; (1): 78-122. (In Russ.). https://doi.org/10.38109/2225-1685-2020-1-78-122.
Review
For citations:
Tyupina V.N., Khidirova L.D. Features of management of patients with pah associated with systemic connective tissue diseases in real clinical practice. Medical alphabet. 2024;(24):57-62. (In Russ.) https://doi.org/10.33667/2078-5631-2024-24-57-62
Views:
75
Email this article 